Cypre - 3D Tumor Model Platform
Cypre’s 3D Tumor Models combine the tumor, stromal and immune compartments in a high throughput format to screen targeted drugs and immunotherapy. In 2021, we partnered with Charles River to offer our 3D Tumor Models for drug discovery and preclinical screening services.
Assaying the Tumor Microenvironment
The tumor microenvironment (TME) involves the complex interplay of heterogeneous tumor cell populations engaging the stromal matrix and immunosuppressive cell types such as fibroblasts that instigate tumor progression and evasion from the body’s immune system. Successful cancer therapy - whether targeted or immunotherapy - must navigate the TME in order to reach and kill the tumor. Cypre’s 3D Tumor Models reconstruct the TME to assay therapeutic efficacy in a physiologically relevant setting.
Assays offered: Tumor Growth, Cytoxicity, T-cell mediated killing, T cell infiltration, Tumor invasion.
Translational tumor complexity, without compromising throughput
Our 3D Tumor Models uses Cypre’s patented 3D hydrogel patterning technology called Symphony® to engineer the tumor microenvironment in 96-well plates. The system constructs the tumor, stroma, and immune cell compartments in proprietary extracellular matrix (ECM) hydrogels, VersaGel®, for assaying critical endpoints such as 3D tumor growth and T-cell mediated killing by infiltrating immune cells. And our extensive work with patient-derived xenograft (PDX) tumors ensures human-relevant heterogeneity in each 3D model.